KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Tax Provisions (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Tax Provisions for 9 consecutive years, with -$390.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions fell 1444.83% year-over-year to -$390.0 million, compared with a TTM value of -$218.0 million through Dec 2025, down 132.25%, and an annual FY2025 reading of -$180.0 million, down 126.63% over the prior year.
  • Tax Provisions was -$390.0 million for Q4 2025 at Teva Pharmaceutical Industries, down from $74.0 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $630.0 million in Q2 2024 and bottomed at -$900.0 million in Q2 2022.
  • Average Tax Provisions over 5 years is -$4.2 million, with a median of $35.0 million recorded in 2023.
  • The sharpest move saw Tax Provisions skyrocketed 4037.5% in 2024, then crashed 1444.83% in 2025.
  • Year by year, Tax Provisions stood at -$24.0 million in 2021, then skyrocketed by 720.83% to $149.0 million in 2022, then crashed by 72.48% to $41.0 million in 2023, then dropped by 29.27% to $29.0 million in 2024, then plummeted by 1444.83% to -$390.0 million in 2025.
  • Business Quant data shows Tax Provisions for TEVA at -$390.0 million in Q4 2025, $74.0 million in Q1 2025, and $29.0 million in Q4 2024.